Nella NuSpec a Smarter Reusable Vaginal Speculum Is Introduced

Nella NuSpec, a smarter reusable vaginal speculum was introduced today by Ceek Women’s Health.

Nella NuSpec was developed in partnership with OBGYN providers and patients through an extensive 5-year R&D process.  The reusable vaginal speculum commonly used today is made from metal and has not changed much from those developed over 150 years ago.  The NuSpec is the first major redesign of the reusable vaginal speculum that takes into account both the patient experience along with unmet provider needs.

Speculum insertion can be uncomfortable for many patients but the NuSpec utilizes a narrow bill—about the size of a regular tampon– to allow for comfortable insertion. Once opened, lateral retractors retain vaginal sidewalls so providers have adequate visibility and access to the cervix.  Nella NuSpec’s medical-grade polymer is temperature neutral, eliminating the jarring cold sensation for patients, and does not require lubrication, reducing the risk of compromised test results. The NuSpec is designed to work on most patients, reducing a clinic’s need to carry an extensive range of speculum styles and sizes.  It is cleaned and sterilized with the same methods used for current metal specula without requiring disassembly.

The Nella NuSpec was successfully tested in a randomized IRB-approved clinical study on women with different body types and across life stages. Because it is a reusable vaginal speculum, the carbon footprint of the NuSpec is also notably lower than existing single-use plastic specula.

“I am very excited to introduce the Nella NuSpec to patients and their providers.  The OBGYNs are tough and will not settle for a suboptimal product. Our clinician advisors have reviewed hundreds of prototypes, evaluating every detail. This device will be game-changing in the care patients receive,” said Fahti Khosrowshahi, CEO and founder of Ceek Women’s Health.

In the U.S. alone, more than 55,000 clinicians use a speculum on average 7-30 times per day, and cumulatively more than 60,000,000 times annually. The Nella NuSpec improves comfort for any patient, but it can make a drastic difference in exam experience for specific populations, such as first-timers, transgender patients, rape or trauma patients, post-menopausal women, and cancer survivors.

“As an OBGYN, we have a responsibility to provide exceptional care and positive experiences for our patients. The Nella line is a brilliant new offering that helps OBGYNs manage exams with more personalization, which is long overdue in the women’s health market,” states Dr. Jessica Shepherd, OBGYN and Ceek Women’s Health Ambassador. “The NuSpec helps me improve the quality of care my patients receive and provides a tool for increased dialogue regarding their exam experience.”

The NuSpec Reusable Vaginal Speculum is part of the Nella line of products designed by Ceek Women’s Health which also includes two accessory products. The Nella VuSleeve, an easy-to-apply clear sheath that provides lateral sidewall retraction and the Nella VuLight, a single use LED illuminator for superior illumination, both can be used with most reusable and disposable vaginal specula.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy